Lilly's Confirms Superiority of Basal Insulin in Three Phase 3 Trials

[Northerner]

Eli Lilly and Co. announced positive top-line results of three completed Phase 3 clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes. The primary efficacy endpoint of non-inferior reduction in hemoglobin A1c (HbA1c) compared to insulin glargine was met in all three trials. Having met the primary endpoints, superiority for HbA1c lowering was examined and, in all three trials, BIL showed a statistically superior reduction in HbA1c compared with insulin glargine.

http://www.dddmag.com/news/2014/05/lillys-confirms-superiority-basal-insulin-three-phase-3-trials